XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaboration Agreements (Tables)
3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of Collaboration Revenue
Revenue disaggregated by collaboration agreement and performance obligation is as follows (in thousands):
Three Months Ended March 31,
20242023
Takeda Collaboration Agreement:
PTV:PGRN Collaboration Agreement(1)
$— $10,000 
Total Takeda Collaboration Revenue— 10,000 
Sanofi Collaboration Agreement
CNS Program License(2)
— 25,000 
Total Sanofi Collaboration Revenue— 25,000 
Biogen Collaboration Agreement
Option Research Services(3)
— 141 
Total Biogen Collaboration Revenue— 141 
Total Collaboration Revenue$— $35,141 
_________________________________________________
(1)Revenue for the three months ended March 31, 2023 from a specified clinical milestone in the Phase 1/2 clinical of DNL593 in patients with frontotemporal dementia-granulin (FTD-GRN).
(2)Revenue for the three months ended March 31, 2023 from a milestone payment triggered and received in January 2023 upon the commencement of dosing in a Phase 2 study of SAR443820/DNL788 in individuals with multiple sclerosis.
(3)Revenue for the three months ended March 31, 2023 was included in the contract liability balance at the beginning of the period.